LAMP5 in presynaptic inhibitory terminals in the hindbrain and spinal cord: a role in startle response and auditory processing

Michinori Koebis\textsuperscript{1}, Shinji Urata\textsuperscript{2}, Yo Shinoda\textsuperscript{3}, Shigeo Okabe\textsuperscript{4}, Tatsuya Yamasoba\textsuperscript{2}, Kazuki Nakao\textsuperscript{1}, Atsu Aiba\textsuperscript{1} and Teiichi Furuichi\textsuperscript{5}\*  

Abstract  
Lysosome-associated membrane protein 5 (LAMP5) is a mammalian ortholog of the \textit{Caenorhabditis elegans} protein, UNC-46, which functions as a sorting factor to localize the vesicular GABA transporter UNC-47 to synaptic vesicles. In the mouse forebrain, LAMP5 is expressed in a subpopulation of GABAergic neurons in the olfactory bulb and the striato-nigral system, where it is required for fine-tuning of GABAergic synaptic transmission. Here we focus on the prominent expression of LAMP5 in the brainstem and spinal cord and suggest a role for LAMP5 in these brain regions. LAMP5 was highly expressed in several brainstem nuclei involved with auditory processing including the cochlear nuclei, the superior olivary complex, nuclei of the lateral lemniscus and grey matter in the spinal cord. It was localized exclusively in inhibitory synaptic terminals, as has been reported in the forebrain. In the absence of LAMP5, localization of the vesicular inhibitory amino acid transporter (VIAAT) was unaltered in the lateral superior olive and the ventral cochlear nuclei, arguing against a conserved role for LAMP5 in trafficking VIAAT. Lamp5 knockout mice showed no overt behavioral abnormality but an increased startle response to auditory and tactile stimuli. In addition, LAMP5 deficiency led to a larger intensity-dependent increase of wave I, II and V peak amplitude of auditory brainstem response. Our results indicate that LAMP5 plays a pivotal role in sensorimotor processing in the brainstem and spinal cord.

Keywords: LAMP5, Startle response, Prepulse inhibition, Inhibitory synaptic terminals, LSO, VGAT

Introduction  
Membrane trafficking is important for the generation of specialized cell structures and functions. In neurons, formation of polarized cell morphology requires long-distance transport of intracellular membrane organelles and membrane proteins to axons and dendrites \cite{1–6}. In presynaptic boutons and postsynaptic dendritic spines, exocytotic and endocytotic membrane trafficking regulates efficacies of synaptic neurotransmission; e.g., regulation of neurotransmitter release probability by exocytosis of synaptic vesicles \cite{7–11} and changes in the postsynaptic response by exo/endocytosis of neurotransmitter receptors \cite{12–14}. In addition to ubiquitously expressed molecules that regulate general membrane trafficking, there are a variety of neuron-specific molecules that exert critical roles in neuronal structure and function \cite{15, 16}.

We recently developed a transcriptome database for various developmental stages of the mouse brain (BrainTx) and have identified several genes whose expression is brain specific and developmentally regulated \cite{17, 18}. A gene encoding lysosome-associated membrane protein 5 (LAMP5) is one such gene that shows distinctive mRNA expression patterns during postnatal stages. Although LAMP5 belongs to the LAMP family based on structural similarity in the LAMP domain, it is different from other LAMP proteins in terms of tissue-specific expression. For example, LAMP5 is almost brain-specific, whereas LAMP1 and LAMP2 are expressed in cells of many tissues besides brain \cite{19}. Moreover, in cortical pyramidal neurons, LAMP5 is mainly accumulated in distinct intracellular vesicles, which do not contain any known markers of classical intracellular transport pathways, and is not targeted to the late endosomal/
lysosomal compartments [20] in which LAMP1 and LAMP2 are primarily localized. Thus, LAMP5 is expected to play a different role from that of LAMP1 and LAMP2 and to contribute to the unique function of the central nervous system (CNS); however, the distribution and function of the protein in the mammalian CNS is not well characterized.

A recent study investigated LAMP5 expression in the mouse forebrain and revealed that it is expressed in subpopulations of GABAergic neurons in the striato-nigral system and the olfactory bulb [21]. The protein is localized to synaptic terminals, where it overlaps with the vesicular GABA transporter or vesicular inhibitory amino acid transporter (VGAT/VIAAT), and deficiency of LAMP5 leads to altered pre-synaptic plasticity in striatopallidal synapses. Interestingly, UNC-46, a LAMP5 ortholog in Caenorhabditis elegans is also localized in the presynaptic terminals of all 26 GABAergic neurons [22]. It is essential for the axonal transport of VIAAT; the unc-46 mutant has disturbed GABA neurotransmission and motor coordination, suggesting a conserved role of LAMP5 as a VIAAT trafficking chaperon in the mammalian brain. However, LAMP5-deficiency in mice does not affect the subcellular localization of VIAAT in striatal neurons, posing the possibility that LAMP5 may be involved in GABA neurotransmission in a different manner in the mammalian brain [21].

There are many inhibitory neurons in the hindbrain and spinal cord of the mammalian CNS, but the expression and the subcellular localization of LAMP5 in these regions have not been reported. Therefore, in the present study, we addressed whether LAMP5 is localized in the inhibitory synaptic terminals and whether it is involved with the axonal transport of VIAAT in the mammalian brain. We investigated the spatiotemporal expression profile of LAMP5 protein in the mouse CNS. We first analyzed 18 different regions of the adult mouse CNS, including the hindbrain regions and the spinal cord, and found that LAMP5 protein was expressed throughout the CNS with prominent expression in the pons, the medulla oblongata and the spinal cord (Fig. 1a). Moderate expression was observed in the inferior colliculus and the striatum, while expression was below the limit of detection in the cerebellum. LAMP5 expression was also observed in hypothalamic tissue; however, this was possibly because of incorporation of flanking regions, such as the ventral pallidum and the substantia nigra, because subsequent immunohistochemical analysis revealed that the flanking regions expressed LAMP5 strongly whereas the hypothalamus itself did not [21] (see below). Interestingly, the expression profile of Lamp5 mRNA was different from that of LAMP5 protein (lower panels in Fig. 1a). On one hand, a striking difference was observed in the cerebral cortex, where the transcript was highly expressed but the protein was barely detectable. On the other hand, the transcript was hardly detected in certain regions like the inferior colliculus and the hypothalamus where the protein was present, indicating that the protein was translated elsewhere and transported to the regions via axonal projections.

We also analyzed LAMP5 expression during postnatal development at postnatal day 3 (P3), P7, P14, P22 and P56 in whole brain (Fig. 1b) and in several brain regions (Fig. 1c). Immunoblotting of whole brain samples revealed that LAMP5 expression increased drastically in the period between weaning and young adulthood (Fig. 1b). However, the expression levels of LAMP5 in each brain region showed regional specificity during development (Fig. 1c). In the striatum, the expression level of LAMP5 increased during postnatal development and reached a peak at P22 (juvenile stage). High expression was already detected at P7 in the pons and medulla, and reached a plateau at P14 that was maintained thereafter. In contrast, expression in cerebellar samples could not be detected at any postnatal stages. These results showed that LAMP5 is widely but specifically expressed in numerous brain regions during postnatal development with prominent expression in the hindbrain and spinal cord.

Restricted distribution of LAMP5 protein in the brain stem

Next, we investigated the distribution of LAMP5 in the adult brain and spinal cord by immunohistochemistry (Fig. 2). Consistent with the immunoblot results, strong immunoreactivity was observed in the pons and the medulla oblongata. The protein was also present in the ventral pallidum (VP) and the substantia nigra pars reticulata (SNr) as previously reported [21] (Fig. 2a).

In coronal hindbrain sections LAMP5 was broadly distributed in the pons and the medulla oblongata with marked expression in the sensory-related nuclei of the pons and cochlear nuclei (Fig. 2b): namely, the ventral part of the nucleus of lateral lemniscus (vNLL), the
principal sensory nucleus of the trigeminal nerve (PSV), the superior olivary complex (SOC) and the ventral and dorsal parts of the cochlear nucleus (VCO and DCO).

In the spinal cord, LAMP5 immunoreactivity was present throughout the dorsal, lateral and ventral horns of the gray matter and also in nerve fibers within the dorsal, lateral and ventral columns of the white matter (Fig. 2c). Similar distribution patterns were observed in the cervical, thoracic and lumbar regions of the spinal cord.

**LAMP5 is expressed in inhibitory projection neurons in the brainstem**

Next, we examined whether LAMP5 was localized to inhibitory synaptic terminals in the hindbrain and the spinal cord. When we double-stained inhibitory axon termini with anti-LAMP5 and anti-VIAAT antibodies, the distributions of LAMP5 and VIAAT were highly similar in the hindbrain and spinal cord (Fig. 3a–b). For example, both VIAAT and LAMP5 showed a strong gradient across the lateral superior olive (LSO) with higher immunoreactivity in the lateral limb of this nucleus (lower panels in Fig. 3a). At a higher magnification, we found that LAMP5 was specifically co-localized with VIAAT and segregated from either vesicular glutamate transporter 1 (VGluT1)- or VGluT2-positive synaptic boutons (Fig. 3c). The co-localization of LAMP5 and VIAAT was also observed in the VCO, the vNLL, the PSV, the caudal pontine reticular formation (PNc) and the ventral and dorsal horn of the spinal cord (Fig. 3c–d and data not shown).

The LSO neurons receive major glycinergic input from principal neurons in the medial nucleus of the trapezoid body (MNTB) (Fig. 3e). According to the Allen Mouse Brain Atlas [23, 24], MNTB neurons express Lamp5 mRNA at a high level (Fig. 3f) but the MNTB itself did not show a strong immunoreactivity against LAMP5 (Fig. 3a, asterisk) and only weak immunoreactivity was detected in the cytoplasm of MNTB principal neurons (Fig. 3g). This suggests that LAMP5 expressed in MNTB neurons was transported to their synaptic terminals located in the LSO.

**Generation of a Lamp5-deficient mouse**

To reveal molecular and physiological functions of LAMP5, we generated a Lamp5 mutant mouse line using the CRISPR/Cas9 system. We used three guide RNAs targeting either exon 2 or the 3′ splice site of intron 5 of the Lamp5 gene and obtained a mutant mouse carrying a deletion spanning from the middle of exon 2 to the 3′ end of intron 5 with a 3-base insertion (Fig. 4a–b). The mutation resulted in the in-frame fusion of the 5′ half of exon 2 and the last exon, and the loss of most of the LAMP5 protein other than the signal peptide. Thus the polypeptide encoded by the mutant allele is predicted to be non-functional (Fig. 4c). The absence of the full-length LAMP5 protein was confirmed by western blotting of whole brain lysates from wild type, and heterozygous and homozygous Lamp5 mutants (Fig. 4d). Hereafter, we call the homozygous mutant Lamp5 KO.
Involvement of LAMP5 in axonal transport of VIAAT

Using Lamp5 KO mice, we examined whether LAMP5 was involved with the axonal transport of VIAAT. LAMP5-expressing MNTB neurons provide major glycinergic input to the LSO neurons; therefore, we investigated VIAAT expression in the LSO. The immunoreactivity for VIAAT and the ratio of VIAAT to VGluT2 were not altered in KO animals (Fig. 5a–b, and data not shown). We also investigated the VCO and failed to detect any change in VIAAT expression in Lamp5 KO mice (Fig. 5c–d). These results indicate that LAMP5 is not essential for the axonal transport of VIAAT in these nuclei.

Exaggerated startle response in Lamp5 KO mice

Next, we performed a series of behavioral tests including tests that evaluate brainstem- and spinal cord-related functions. Open field, elevated plus maze and rotarod tests showed that Lamp5 KO mice have no overt abnormalities in locomotor activity, anxiety-related behavior, motor coordination and motor learning (Fig. 6a–c). Interestingly, however, we found that Lamp5 KO mice showed increased startle response to unexpected loud noise (Fig. 6d). The mutants also showed decreased prepulse inhibition (PPI) of the acoustic startle reflex (Fig. 6e), indicating that LAMP5 deficiency led to abnormal sensorimotor processing. Because LAMP5 was expressed in the inhibitory synaptic terminals in the cochlear nuclei, the SOC and the vNLL, all of which are involved with auditory processing, we assumed that the increased startle reflex in Lamp5 KO mice might result from increased excitability of the brainstem auditory circuit. We therefore analyzed auditory brainstem response (ABR) to tone-burst stimuli at various
frequencies (4, 8, 16 and 31.25 kHz) (Fig. 7). ABR threshold was not different between the genotypes (Fig. 7b), but the amplitude of ABR appeared to be larger in KO animals (Fig. 7a). When we analyzed the peak amplitude of ABR waves at 16 kHz, wave I, II and V were significantly larger especially at the higher sound pressure level. Meanwhile, a tactile stimulus also elicited an increased startle response in the KO mice (Fig. 6f), indicating that there was no stimulus specificity in the exaggeration of the startle response in KO mice. Taken together, knockout of the Lamp5 gene led to an increased startle response and smaller PPI as well as an increased ABR, indicating that LAMP5 plays an essential role in regulating brainstem- and spinal cord-mediated sensorimotor and auditory processing ability. These findings are consistent with the immunohistochemistry findings.

**Discussion**

In the present study, we characterized the spatial and temporal distribution of LAMP5 in the mouse hindbrain and spinal cord. We found that LAMP5 was expressed in the pons and medulla oblongata at relatively high levels by P7. According to the Allen Developing Mouse Brain Atlas [25], expression of Lamp5 mRNA can be observed in the hindbrain and spinal cord as early as at embryonic day 11.5 (E11.5) and then spreads to the midbrain and forebrain regions after birth [23], as also shown in this study. In the spinal cord, synaptic contact occurs on motor neurons at E11.5 and the first synaptic activity can be recorded the following day [26–30], whereas synaptogenesis occurs postnatally in the forebrain and peaks in the juvenile stage [31]. Thus, the
The temporal transition of LAMP5 expression was consistent with the synaptic formation in the striatum, pons, and medulla.

Our immunohistochamical analysis showed that LAMP5 was localized exclusively in inhibitory synaptic terminals in the pons and spinal cord, suggesting its role in inhibitory neurotransmission. Two studies have reported that LAMP5 and its ortholog function in GABAergic nerve terminals [21, 22]. One showed that in *C. elegans*, the LAMP5 ortholog, UNC-46, is expressed in every GABAergic motor neuron and acts as a sorting chaperone that localizes VIAAT to synaptic terminals [22]. In *unc-46* mutants, frequency of miniature currents is severely reduced possibly due to a reduced number of vesicles that harbored the transporter. The other study showed that in mammals, LAMP5 is localized in inhibitory synaptic terminals of granule cells of the olfactory bulb and in striatal neurons [21]; however, the study also showed that LAMP5 is not essential for correct localization of VIAAT in these neurons, arguing against the conserved role of axonal trafficking of the transporter. In the present study, we showed that LAMP5 has little to do with terminal localization of VIAAT in the brainstem. Nevertheless, LAMP5-deficiency has a complex impact on the striatopallidal synapse function: the frequency of activity-independent currents is increased while the evoked release probability is decreased as indicated by a strong paired-pulse facilitation of inhibitory postsynaptic currents [21]. Although it is yet unknown how LAMP5 affects presynaptic release machinery, the study suggested the importance of LAMP5 on fine-tuning of GABAergic neurotransmission. We speculate that LAMP5 achieves its function by regulating turnover of some membrane proteins or vesicles, because a study of cortical neurons that showed LAMP5 was subjected to endocytosis and localized in uncharacterized early endocytic organelles [20]. Taken together, these results suggest that LAMP5-deficiency can lead to a compromised neurotransmission of inhibitory synapses in the hindbrain and spinal cord.

LAMP5 deficiency did not cause any overt behavioral abnormality but specifically led to increased startle responses to both auditory and tactile stimuli. Interestingly, dysfunction of glycinergic neurotransmission, which is a major source of synaptic inhibition in the hindbrain and spinal cord, is known to cause exaggerated startle response. For example, the mouse mutant *spasmodic*, which carries a mutation in the gene encoding the glycine receptor subunit alpha 1 (*Glra1*) that decreases its ligand binding affinity, presents massive tremor and exaggerated startle response to sound and touch three weeks after birth [32–34]. Similar phenotypes are caused by mutations in genes encoding glycine receptor subunit beta (*Glb* [35, 36], glycine transporter 2 (*Slc6a5*) [37] or gephrin [38], which is required in glycine receptor clustering [39]. Therefore, one possible explanation of the increased startle response is that LAMP5 deficiency led to dysfunctional currents.
glycinergic neurotransmission in the brainstem and spinal cord. Auditory and tactile stimuli are conveyed via the auditory and trigeminal sensory pathway, respectively, to giant neurons in the PnC. The neurons send direct projections to motor neurons that innervate facial and skeletal muscles and elicit movement of star- } 


tle reflex. LAMP5 can potentially affect startle response either upstream or downstream from the PnC because the protein was expressed both in nuclei composing the auditory and trigeminal pathways (e.g., VCO and PSV) and in the ventral horn of spinal cord where somata of motor neurons exist. The startle response can also be potentiated by fear and anxiety [40]; however, because our behavioral analysis showed that LAMP5 deficiency did not affect emotional behavior, and a study from another group showed that it even decreases anxiety [21], it is unlikely that the startle response was potentiated by the animals’ anxious state.

The normal ABR threshold of LAMP5-deficient mice indicates that function of the cochlear hair cell is conserved. However, the mutant mice showed a larger increase in peak amplitude of waves I, II and V than wild type controls as the sound pressure level of auditory stimuli increased. The larger amplitude of wave I indicates auditory input evokes greater neuronal activity already at the cochlear spiral ganglion. The function and expression of LAMP5 in the cochlea has yet to be shown, but the protein can possibly regulate the cochlear output via SOC neurons because the SOC gives rise to the olivocochlear system that is involved with a descending control of the cochlea [41]. Especially, the medial olivocochlear system (MOCS) is a strong candidate that may lead the altered ABR in Lamp5 KO animals. Several studies demonstrated that electrical stimulation of the MOCS decreases activity of the auditory nerve by inhibiting the active mechanical amplification process of the outer hair cells [42–45]. The MOCS activity depends on sound pressure level of input [46]; therefore, a compromised function of the MOCS will increase auditory nerve responses especially when a loud auditory stimulus is applied. Because the input/output function of ABR waves was increased in Lamp5 KO mice, we assume that LAMP5 deficiency brings about functional deficits in the MOCS thereby enhancing neural activity of the cochlear nerve at higher intensity of sound input. The MOCS stems from large multipolar neurons that reside in...
the ventral nucleus of the trapezoid body (VNTB), where neurons highly express Lamp5 mRNA according to Allen Mouse Brain Atlas. Thus it is likely that LAMP5 functions in the MOCS. Thus elevated response to auditory stimuli is considered to contribute at least in part to the potentiated auditory startle response.

The present study showed LAMP5 to be expressed widely in the inhibitory synaptic terminals of the pons, medulla oblongata and spinal cord and indicates a role in the acoustic and tactile startle reflex. Our results exclude the possibility that the exaggerated startle response in Lamp5-deficient mice was caused by decreased axonal trafficking of VIAAT. Further studies will elucidate the detailed physiological properties of LAMP5 in this reflex pathway.

Methods

Animals

C57BL/6J mice were purchased from CLEA Japan, Tokyo, Japan. Recipient ICR mice were purchased from Charles River Laboratories JAPAN, Kanagawa, Japan. All animals were treated according to the recommendations and protocols approved by the Animal Care and Use Committee of Tokyo University of Science and by the Animal Welfare Committee of the University of Tokyo. Animals were housed in an environment with a 12-h/12-h light/dark cycle (daytime 8:00–20:00) with controlled temperature (23 ± 2 °C) and humidity (55 ± 10%) and ad libitum access to food and water.

Cas9 mRNA and sgRNA preparation

A plasmid template for in vitro transcription of Cas9 mRNA was kindly provided by Dr. T. Mashimo (Kyoto University). The plasmid encodes a Cas9 protein flanked by SV40 nuclear localization signals with a 90-bp poly(A) tail in the 3′-untranslated region, which facilitates its translation in zygotes [47]. Cas9 mRNA was transcribed using a MessageMAX T7 ARCA-Capped Message Transcription Kit (CELLSCRIPT, Madison, WI, USA), polyadenylated with an A-Plus Poly(A) Polymerase Tailing Kit.
Koebis et al. Molecular Brain (2019) 12:20

Page 9 of 13

**KO** et al. Molecular Brain and GCGATGTACTTATTAACTGC

**KO** mRNA and sgRNA were delivered by electroporation to C57BL/6J embryos at the pronuclear stage as

**KO**

**KO** were designed to target either exon 2 or 6 of the **KO** (CELL SCRIPT) and purified using a MEGAClear Kit (Life Technologies). Three single guide RNAs (sgRNAs) were designed to target either exon 2 or 6 of the **KO** (Fig. 4). Their protospacer sequences with PAM (underlined) were as follows: CTCTTCGGGTTTC GTGGAA, AATGGGACGTGTCATCGG and GCATGTCATATTCGCGG. These protospacers were cloned into BsaI-digested pDR274 vector (Addgene ID #42250) and the resulting plasmids served as templates for in vitro transcription. The sgRNAs were transcribed using a MEGAshortscript T7 Transcription Kit (Thermo Fisher Scientific K.K., Tokyo, Japan) and purified using a mini Quick Spin Column (Roche Diagnostics K.K., Tokyo, Japan). All procedures were performed according to the manufacturers’ instructions.

**KO**

**KO** mRNA and sgRNA were delivered by electroporation to C57BL/6J embryos at the pronuclear stage as described previously with slight modifications [48]. Briefly, the embryos were washed three times with Opti-MEM I (Thermo Fisher Scientific) supplemented with 0.1% polyvinylalcohol (PVA) and once with 0.1% PVA-Opti MEM I containing **KO** mRNA (400 ng/μl) and the three sgRNAs (100 ng/μl each). Then the embryos were placed in a line in the gap of an electrode (LF501PT1–10, BEX, Tokyo, Japan) filled with RNA-containing 0.1% PVA-Opti-MEM I (total 5 μl in volume) and electroporation was performed using a CUY21EDIT II electroporator (BEX). After electroporation, the embryos were immediately collected from the electrode chamber and transferred into oviducts of 0.5-day-post-coitum recipients.

**KO** and **KO** mice

Genomic DNA was extracted from mouse tail biopsies to serve as templates for genotyping PCR. The PCR primers for the **KO** locus were as follows: Fw, AATA TGAGTTTGTTGCGCGGT; Rv, TCATTGCATTGCCT CGGTAA. The genotypes of the founder generation were determined by sequencing the amplified PCR fragment directly. One allele of a founder male had a deletion spanning from exon 2 to 6 (Fig. 4a-b), which resulted in truncation of most of the encoded polypeptide (Fig. 4c). This male was mated with C57BL/6J females to obtain F1 mice. For biochemical and behavioral analyses, we used F2 and F3 generation of the mice.

**KO**

An anti-LAMP5 polyclonal antibody was raised in rabbit against the peptide “QVQIPRDRSQYKHM”, corresponding to the cytoplasmic tail of LAMP5 (Fig. 4c). We confirmed the specificity of the antibody to LAMP5 by immunoblotting and immunohistochemistry with **KO** KO samples (Fig. 4d and Additional file 1). An anti-LAMP5 guinea pig polyclonal antibody (#412005) was purchased from Synaptic Systems (Goettingen, Germany). This antibody was used only for co-immunostaining of brainstem and spinal cord slices (Fig. 3). An anti-β-actin (#A2228) mouse monoclonal antibody was purchased from Sigma-Aldrich Japan (Tokyo, Japan). An anti-VGAT/VIAAT mouse monoclonal antibody (#131011) was purchased from Synaptic Systems. An anti-VGAT/VIAAT guinea pig polyclonal antibody, and anti-VGluT1 and anti-VGluT2 goat polyclonal antibodies were kindly provided by Dr. Masahiko Watanabe (Hokkaido University). Horseradish peroxidase (HRP)-conjugated anti-rabbit IgG (H + L) (#474–1506) secondary antibody was purchased from KPL (Gaithersburg, MD, USA), and HRP-conjugated anti-rabbit IgG (H + L) (#711–035-152) and anti-mouse IgG (H + L) (#715–035-152) secondary antibodies were from Jackson ImmunoResearch (West Grove, PA, USA). Alexa Fluor 488-labeled donkey anti-rabbit IgG (H + L) (#A21206), goat anti-guinea pig IgG (H + L) (#A11073) and donkey anti-goat IgG (H + L)
and 2–ing buffer [1 × PBS containing 0.2% (v/v) Triton X-100 and 2–5% (v/v) donkey serum (D9663, Sigma-Aldrich)] for 30 min before incubation with primary antibody in blocking buffer for 2 h or overnight at room temperature. The sections were then washed three times with PBS and incubated with secondary antibody for 2 h at room temperature. After three washes with PBS, the sections were mounted using VECTASHIELD Mounting Medium (Vector Laboratories, Burlingame, CA, USA). Images were obtained using a fluorescence microscope (BZ-8000, KEYENCE, Osaka, Japan) and a confocal laser microscope (SP5, Leica Microsystems, Wetzlar, Germany). For quantitative analysis of immunoreactivity, images were obtained using a confocal microscope with the pinhole open to be the maximum and were processed using Image J software (v.1.51) [49]. Regions of interest (ROIs) were drawn manually by visual inspection. A rectangular ROI was also chosen in an area where a specimen was not present to serve as a background. Background-subtracted mean gray values for each mouse were pooled and averaged across mice of each genotype. At least three sections per mouse were used.

**Behavioral tests**

Lamp5 KO males and littermate control males were subjected to behavioral tests. Cohort A (n = 8 for each genotype) was subjected to open field, elevated plus maze, rotarod and tactile startle response tests in this order at 12 weeks of age. Cohort B (n = 5 for each genotype) was subjected to auditory startle response and prepulse inhibition (PPI) tests at 13 weeks of age. All mice were habituated to the testing room for at least 1 h before each experiment.

**Open field test**

Mice were placed in the center of the open field (75 cm diameter) and allowed to explore freely the arena for 5 min under bright light conditions (600 lx). Their movement was recorded via a camera mounted above the arena, and their activity was measured automatically using Smart 3.0 video tracking software (Panlab, Barcelona, Spain). The open field was divided into an inner circle (50 cm diameter), and an outer area surrounding the inner circle. Measurements included total distance traveled and time spent in the inner and outer sections. The open field arena was cleaned with 70% ethanol and wiped with paper towels between each trial.

**Elevated plus maze test**

The elevated plus-maze consisted of two open arms (29.5 cm long × 6 cm wide), two closed arms surrounded by wall (15 cm high) and a central platform (6 cm × 6 cm) halfway between all arms. The entire apparatus was elevated to height of 55 cm above floor level. Mice were placed in the central platform facing an open arm and allowed to move freely through the maze for 10 min under moderate light conditions (25 lx). Their behavior
was recorded via a camera mounted above the apparatus. Time spent in the open and closed arms was measured. The maze was cleaned with 70% ethanol and wiped with paper towels between each trial.

**Rotarod test**

The rotarod (Muromachi Kikai, Tokyo, Japan) consisted of a gritted metal roller (3 cm in diameter). A mouse was placed on the rotating roller and the time it remained on the roller was measured. The rotation speed of the roller was initially 4 rpm and increased linearly to 40 rpm over 300 s. One trial was carried out per day and the test was conducted for four consecutive days.

**Startle response test and PPI test**

The startle response was measured using an SR-Lab system (San Diego Instruments, San Diego, CA, USA). A mouse was placed in a small/medium animal enclosure (12.7 cm, 3.8 cm inner diameter) under moderately bright light conditions (260 lx) and was allowed to acclimate for 10 min. The movement of the animal in the startle chamber was measured by a piezoelectric accelerometer mounted under the enclosure at the sampling rate of 1 kHz. For the tactile startle response test, animals were subjected to 20 startle trials and five no-stimulus trials. In each startle trial, animals received an air-puff at the pressure of 0.1 MPa from a tube installed through a hole on the top of the enclosure. The puff of air lasted 100 msec. During the session, including the acclimation period, background white noise of 73 dB was continually present to reduce responses induced by noise from the air tubing. For the auditory startle response and PPI test, the animal then received 20 startle trials, 10 no-stimulus trials and 40 PPI trials. The inter-trial intervals were between 10 and 20 s and the total session lasted 17 min. The startle trial consisted of a single 120 dB white noise burst lasting 40 ms. The PPI trial consisted of a prepulse (20 ms burst of white noise at 69, 73, 77 or 81 dB intensity) followed, 100 ms later, by the startle stimulus (120 dB, 40 ms white noise). Each of the four prepulse trials (69, 73, 77 or 81 dB) was presented 10 times. Five consecutive startle trials were presented at the beginning and end of the session. The remainder of sixty different trials was presented pseudorandomly, ensuring that each trial was presented 10 times and that no two consecutive trials were identical. During the session, including the acclimation period, background white noise of 65 dB was continually present. The recording started 20 ms after startle stimulus onset and lasted for 60 ms. The largest amplitude in the recording window was taken as the startle amplitude for the trial. Basal startle amplitude was determined as the mean startle amplitude of the 20 startle trials. PPI (%) was calculated as follows: 100 x (pulse-alone response – prepulse-pulse response)/pulse-alone response, in which the prepulse-pulse response was the mean of the 10 PPI trials (69, 73, 77 or 81 dB) and the pulse-alone response was the basal startle amplitude.

**Auditory brainstem response**

ABR was recorded from mouse cohort A after the series of behavioral analyses as described previously [50]. Briefly, mice were anesthetized with ketamine hydrochloride (50 mg/kg, i.p.) and xylazine hydrochloride (10 mg/kg, i.p.). Before the ABR measurements, the external auditory canals and tympanic membranes were confirmed to be normal in all mice. Subdermal needle electrodes were placed on the vertex (active electrode), in the postauricular area of the measured ear (reference electrode), and in the postauricular area of the opposite ear (ground electrode). ABRs were evoked with tone-bursts (5 ms duration at 4, 8, 16, and 31.25 kHz) and measured by a recording system (Neurpack Σ MEB2208, Nihon Kohden). A speaker was placed 10 cm from the tragus of the stimulated ear. ABRs from 500 trials were averaged at each sound intensity. ABR thresholds were estimated by changing the intensity in 5 dB steps and finding the lowest sound intensity where reliable response peaks were detected. Peak amplitudes of ABR waves I, II and V were defined as follows: wave I, height from the baseline (0 ms); wave II, height from the subsequent trough; wave V, height from the previous trough.

### Additional file

**Additional file 1:** Specificity of the anti-LAMP5 antibody in immunohistochemical staining. (PNG 348 kb)

### Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| ABR | Auditory brainstem response; CNS | Central nervous system; CRISPR | Clustered regularly interspaced short palindromic repeat; DCO | Dorsal parts of the cochlear nucleus; DNA | Deoxyribonucleic acid; E | Embryonic day; GABA | Gamma-Aminobutyric acid; Gapdp | Glyceraldehyde-3-phosphate dehydrogenase; HRP | Horse raddish peroxidase; KO | Knock out; LAMP | Lysosome-associated membrane protein; LSO | Lateral superior olive; MNTB | Medial nucleus of the trapezoid body; mRNA | Messenger ribonucleic acid; MSO | Medial superior olive; P | Postnatal day; PAGE | Polyacrylamide gel electrophoresis; PAM | Protospcacer adjacent motif; PBS | Phosphate-buffered saline; PCR | Polymerase chain reaction; PnC | Caudal pontine reticular formation; PPI | Prepulse inhibition; PSV | Principal sensory nucleus of the trigeminal; PVA | Polyvinylalcohol; PVCN | Posteroventral cochlear nucleus; PVD | Polyvinylidene difluoride; RNA | Ribonucleic acid; R0I | Region of interest; RT | Reverse transcription; SDS | Sodium dodecyl sulfate; sgRNA | Single guide ribonucleic acid; Shn | Substantia nigra pars reticulata; SOC | Superior olivary complex; SPN | Superior paralivary nucleus; TBS | Tris-buffered saline; VCO | Ventral parts of the cochlear nucleus; VGAT | Vesicular GABA transporter; VGluT | Vesicular glutamate transporter; WAAT | Vesicular inhibitory amino acid transporter; vNLL | Ventral part of the nucleus of lateral lemniscus; WT | Wild type

### Acknowledgements

The authors thank Dr. M Watanabe (Hokkaido University) for providing antibodies. We acknowledge support by the CDBIM animal facilities. We thank Jeremy Allen, PhD, from Edanz Group (http://www.edanzediting.com/) for editing a draft of this manuscript.
Funding
This work was supported by JSPS KAKENHI Grant Number 17H03563 and 17K14973.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
MK designed, performed and analyzed all the experiments except ABR and wrote the paper. SU, SO and TY arranged and performed the ABR measurement and coordination. All authors reviewed the results, revised the paper and approved the final version of manuscript.

Ethics approval
All animals were treated according to the recommendations and the protocols approved by the Animal Care and Use Committee of Tokyo University of Science and by the Animal Welfare Committee of the University of Tokyo.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no conflicts of interest with the contents of this article.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Laboratory of Animal Resources, Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo 113-0033, Japan. 2Department of Otolaryngology, Faculty of Medicine, The University of Tokyo, Tokyo 113-8655, Japan. 3Department of Environmental Health, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo 192-0392, Japan. 4Department of Cellular Neurobiology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-0033, Japan. 5Department of Applied Biological Sciences, Tokyo University of Science, Chiba 278-8510, Japan.

Received: 26 December 2018 Accepted: 25 February 2019
Published online: 12 March 2019

References
1. Nishimura T, Kato K, Yamaguchi T, Fukata Y, Ohno S, Kaibuchi K. Role of the PAR-3–PKC3 complex in the establishment of neuronal polarity. Nat Cell Biol. 2004;6(4):328–34.
2. Horiguchi K, Hanada T, Fukui Y, Chichib A. Transport of IP3 by GAKIN, a kinesin-3 family protein, regulates neuronal cell polarity. J Cell Biol. 2006;174(3):425–36.
3. Kaptein LC, Hoogenraad CC. Which way to go? Cytoskeletal organization and polarized transport in neurons. Mol Cell Neurosci. 2011;46(1–2):19–20.
4. Wang T, Liu Y, Xu HJ, Deng CY, Wu KY, Zhu J, et al. Lgl1 activation of Rab10 promotes axonal membrane trafficking underlying neuronal polarization. Dev Cell. 2011;21(3):431–44.
5. Lalli G. RabA and the exocytosis complex influence neuronal polarity through PAR-3 and APIC. J Cell Sci. 2009;122(10):1499–506.
6. Lalli G. Regulation of neuronal polarity. Exp Cell Res. 2014;328(2):267–75.
7. Jahn R, Fasshauer D. Molecular machineries governing exocytosis of synaptic vesicles. Nature. 2012;490(7419):201–7.
8. Sadakata T, Shinoda Y, Selke Y, Saruta C, Itakura M, Takahashi M, et al. Interaction of calcium-dependent activator protein for secretion I (CAPS1) with the class II ADP-ribosylation factor small GTases is required for dense-core vesicle trafficking in the trans-Golgi network. J Biol Chem. 2010;285(49):38710–9.
9. Sadakata T, Sekine Y, Oka M, Itakura M, Takahashi M, Funuchi T. Calcium-dependent activator protein for secretion 2 interacts with the class II ARF small GTPases and regulates dense-core vesicle trafficking. FEBS J. 2012;279(3):384–94.
10. Sadakata T, Kakegawa W, Shinoda Y, Hosono M, Kato-Sembra R, Selke Y, et al. CAPS1 deficiency perturbs dense-core vesicle trafficking and Golgi structure and reduces presynaptic release probability in the mouse brain. J Neurosci. 2013;33(44):17326–34.
11. Shinoda Y, Ishii C, Fukazawa Y, Sadakata T, Ishii Y, Sano Y, et al. CAPS1 stabilizes the state of readily releasable synaptic vesicles to fusion competence at CA3–CA1 synapses in adult hippocampus. Sci Rep. 2016;6:31540.
12. Anggono V, Huganir RL. Regulation of AMPA receptor trafficking and synaptic plasticity. Curr Opin Neurobiol. 2012;22(3):461–9.
13. Kakegawa W, Kato A, Narumi S, Miura E, Motohashi J, Takahashi A, et al. Optogenetic control of synaptic AMPA receptor endocytosis reveals roles of LTD in motor learning. Neuron. 2018;99(5):985–98.
14. Malinov R, Malenka RC. AMPA receptor trafficking and synaptic plasticity. Annu Rev Neurosci. 2002;25:103–26.
15. John R, Scheller RH. SNAREs — engines for membrane fusion. Nat Rev Mol Cell Biol. 2006;7(9):631–43.
16. D’Adamo P, Masetti M, Bianchi V, More L, Mignogna ML, Giannandrea M, et al. RAB GTPases and RAB-interacting proteins and their role in the control of cognitive functions. Neurosci Biobehav Rev. 2014;46:302–14.
17. Sato A, Selke Y, Saruta C, Nishibe H, Morita N, Sato Y, et al. Cerebellar development transcriptome database (CDT-DB): profiling of spatio-temporal gene expression during the postnatal development of mouse cerebellum. Neural Netw. 2008;21(8):1056–69.
18. The Brain Transcriptome Database. http://www.cdtb.neuroinfo.jp/CDT/Top.jsp. Accessed 10 Apr 2014.
19. Wilke S, Krause J, Buessov K. Crystal structure of the conserved domain of the DC lysosomal associated membrane protein: implications for the lysosomal glycolcamic. BMC Biol. 2012;10:662.
20. David A, Tiveron M-C, Defays A, Beclin C, Carnosseto V, Gatti E, et al. BAD-LAMP defines a subset of early endocytic organelles in subpopulations of cortical projection neurons. J Cell Sci. 2007;120(2):353–65.
21. Tiveron M-C, Beurrier C, Ceni C, Andreiambao N, Combes A, Koehl M, et al. LAMPS fine-tunes GABAergic synaptic transmission in defined circuits of the mouse brain. PLoS One. 2016;11(6):e0157052.
22. Schuske K, Palfreyman MT, Watanabe S, Jorgensen EM. UNC-46 is required for the KIF3 complex in the establishment of neuronal polarity. Nat Cell Biol. 2006;8(10):1013–23.
23. The Allen Developing Mouse Brain Atlas. http://developingmouse.brain-inf.jp/BrainAtlas. Accessed 18 Sept 2017.
24. Kanjhan R, Noakes PG, Bellingham MC. Emerging roles of Filopodia and dendritic spines in Motoneuron plasticity during development and disease. Neural Plast. 2016;2016:3423267.
25. Vaughn JE, Henrikson CK, Grieshaber JA. A quantitative study of synapses on motor neuron dendritic growth cones in developing mouse spinal cord. J Cell Biol. 1974;66(3):664–72.
26. Vaughn JE, Sims T, Nakashima M. A comparison of the early development of axodendritic and axosomatic synapses upon embryonic mouse spinal motor neurons. J Comp Neurol. 1977;175(1):79–100.
27. Vaughn JE, Barber RP, Sims TJ. Dendritic development and preferential growth into synaptogenic fields: a quantitative study of Golgi-impregnated spinal motor neurons. Synapse. 1988;2(1):69–78.
28. Vaughn JE. Fine structure of synaptogenesis in the vertebrate central nervous system. Synapse. 1989;3(2):355–85.
29. Tepper JM, Sharpe NA, Koos TZ, Trent F. Postnatal development of the rat neostriatum: electrophysiological, light- and electron-microscopic studies. Dev Neurosci. 1998;20(2–3):125–45.
30. Lane PW, Ganser AL, Kemer AL, White WF. Spasmodic, a mutation on chromosome 11 in the mouse. J Hered. 1987;78(6):353–6.
31. Ryun SG, Backwaltter MS, Lyons JW, Handford CA, Segura L, Shiang R, et al. A missense mutation in the gene encoding the alpha 1 subunit of the inhibitory glycine receptor in the spasmatic mouse. Nat Genet. 1994;7(2):131–5.
32. Saul B, Schmieden V, Kulling C, Mulhardt C, Gass P, Kuhre J, et al. Point mutation of glycine receptor alpha 1 subunit in the spasmatic mouse affects agonist responses. FEBS Lett. 1994;350(1):71–6.
35. Chai CK. Hereditary spasticity in mice. J Hered. 1961;52(5):241–3.
36. Kingsmore SF, Giros B, Suh D, Bieniarz M, Caron MG, Seldin MF. Glycine receptor beta-subunit gene mutation in spastic mouse associated with LINE-1 element insertion. Nat Genet. 1994;7(2):136–42.
37. Gomez J, Ohno K, Hultmann S, Arnsen W, Eulenburg V, Richter DW, et al. Deletion of the mouse glycine transporter 2 results in a hyperseraklesia phenotype and postnatal lethality. Neuron. 2003;40(4):797–806.
38. Feng GP, Tintrup H, Kirsch J, Nichol MC, Kuhse J, Betz H, et al. Dual requirement for gephyrin in glycine receptor clustering and molybdoenzyme activity. Science. 1998;282(5392):1321–4.
39. Kirsch J, Wolters I, Tillier A, Betz H. Gephyrin antisense oligonucleotides prevent glycine receptor clustering in spinal neurons. Nature. 1999;366(6547):745–8.
40. Grillon C. Models and mechanisms of anxiety: evidence from startle studies. Psychopharmacology. 2008;199(3):421–37.
41. Ciuman RR. The efferent system or olivocochlear function bundle — fine regulator and protector of hearing perception. Int J Biomed Sci. 2010;6(4):276–89.
42. Galambos R. Suppression of auditory nerve activity by stimulation of efferent fibers to cochlea. J Neurophysiol. 1956;19(5):424–37.
43. Desmedt JE, Monaco P. Mode of action of the efferent olivo-cochlear bundle on the inner ear. Nature. 1961;192:1263–5.
44. Fex J. Auditory activity in centrifugal and centripetal cochlear fibres in cat. A study of a feedback system. Acta Physiol Scand Suppl. 1962;189:1–68.
45. Wiederhold ML, Kiang NY. Effects of electric stimulation of the crossed olivocochlear bundle on single auditory-nerve fibers in the cat. J Acoust Soc Am. 1970;48(4):950–65.
46. Liberman MC, Brown MC. Physiology and anatomy of single olivocochlear neurons in the cat. Hear Res. 1986;24(1):17–36.
47. Yoshimi K, Kunihito Y, Kaneko T, Nagahora H, Voigt B, Mashimo T. ssODN-mediated knock-in with CRISPR-Cas for large genomic regions in zygotes. Nat Commun. 2016;7:10431.
48. Hashimoto M, Takemoto T. Electroporation enables the efficient mRNA delivery into the mouse zygotes and facilitates CRISPR/Cas9-based genome editing. Sci Rep. 2015;5:11315.
49. Schneider CA, Radoab WD, Elceit KW. NIH image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9(7):671–5.
50. Fujimoto C, Iwasaki S, Urata S, Morishita H, Sakamaki Y, Fujioka M, et al. Autophagy is essential for hearing in mice. Cell Death Dis. 2017;8(5):e2780.